Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: A retrospective study

被引:0
|
作者
Xu, Chenfeng [1 ,2 ]
Zeng, Fang [1 ,2 ]
Xu, Qiling [1 ,2 ]
Yang, Yu [1 ,2 ]
Zhang, Yu [1 ,2 ]
Shi, Chen [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Peoples R China
[2] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
Polymyxin B; Intracranial infection; Intrathecal; Intraventricular; Carbapenem-resistant Acinetobacter; baumannii; CARE-ASSOCIATED VENTRICULITIS; CLINICAL-PRACTICE GUIDELINES; GRAM-NEGATIVE BACILLI; MULTIDRUG-RESISTANT; DISEASES SOCIETY; COLISTIN; MENINGITIS; DRAINAGE;
D O I
10.1016/j.ijantimicag.2024.107334
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the therapeutic regimen, efficacy and safety of intrathecal or intraventricular (ITH/IVT) administration of polymyxin B for hospital-acquired central nervous system (CNS) infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). Methods: A retrospective study was undertaken of patients with CNS infections caused by CRAB treated with ITH/IVT combination therapy. The primary outcome was the clinical efficacy of treatment. The secondary outcomes were the bacterial clearance rate and the safety of therapy. Results: In total, 35 patients who received ITH [ n = 13 (37.1%)] or IVT [ n = 22 (62.9%)] polymyxin B as combination therapy were included in this study. The median duration of ITH/IVT polymyxin B therapy was 9 (interquartile range 7-11) days. The overall clinical cure rate and bacterial clearance rate were 77.1% and 85.7%, respectively. No adverse effects considered to be related to ITH/IVT polymyxin B were recorded. Clinical failure was independently associated with an Acute Physiology and Chronic Health Evaluation II score >= 15 [odds ratio (OR) 1.24, 95% confidence interval (CI) 1.05-1.42; P = 0.038] and a Glasgow Coma Scale score <8 (OR 0.69, 95% CI 0.49-0.88; P = 0.029). Early administration ( <4 days of infection onset) of ITH/IVT polymyxin B therapy resulted in a significantly higher clinical cure rate (OR 0.65, 95% CI 0.49- 1.12; P < 0.001), and may reduce the length of treatment and adverse effects. Conclusions: ITH/IVT administration of polymyxin B is a valid alternative for the treatment of CNS infections caused by CRAB. Early use of ITH/IVT polymyxin B can result in greater clinical success. (c) 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:7
相关论文
共 20 条
  • [11] Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: a retrospective cohort study
    Chen, Jing
    Xia, Binbin
    Liu, Yang
    Sun, Wenfang
    Liu, Fang
    Pang, Jingyao
    Cheng, Hua
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [12] The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study
    Xu, Ying
    Luo, Xuemei
    Yuan, Binbin
    Liang, Pei
    Liu, Ning
    Dong, Danjiang
    Ge, Weihong
    Gu, Qin
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (04) : 820 - 825
  • [13] 'Effectiveness of various sulbactam-based combination antibiotic therapy in the management of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in a tertiary care Health centre'
    Chaudhary, Monika
    Kumar, Deepak
    Meena, Durga Shankar
    Midha, Naresh Kumar
    Bohra, Gopal Krishana
    Tak, Vibhor
    Samantaray, Subhashree
    Kaur, Navneet
    Neetha, T. R.
    Mohammed, Sadik
    Sharma, Ankur
    Kothari, Nikhil
    Bhatia, Pradeep Kumar
    Garg, M. K.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2024, 52
  • [14] Combined Strategy for Post-Operative Patients with Central Nervous System Infections Caused by Extensively Drug-Resistant/Pan-Drug-Resistant Acinetobacter baumannii: A Retrospective Study
    Chang, Jian-bo
    Chen, Yihao
    Wang, He
    Ma, Xiaojun
    Zhang, Xiao
    Wu, Hao
    Ma, Baitao
    Zuo, Wei
    Ma, Wenbin
    Wang, Renzhi
    Wei, Junji
    SURGICAL INFECTIONS, 2020, 21 (10) : 853 - 858
  • [15] Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae: A Propensity Score-Matched Cohort Study
    Zha, Lei
    Zhang, Xue
    Cheng, Yusheng
    Xu, Qiancheng
    Liu, Lingxi
    Chen, Simin
    Lu, Zhiwei
    Guo, Jun
    Tefsen, Boris
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [16] Clinical Presentations and Outcomes of Post-Operative Central Nervous System Infection Caused by Multi-Drug-Resistant/Extensively Drug-Resistant Acinetobacter baumannii: A Retrospective Study
    Wen Liang
    Zhu Yuan-Run
    Yan Min
    SURGICAL INFECTIONS, 2019, 20 (06) : 460 - 464
  • [17] Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study
    Bu, Wei
    Wang, Chengyu
    Wu, Yuan
    Zhang, Peng
    Zhang, Nengfang
    Han, Ying
    Xu, Xiaona
    Li, Sha
    Cai, Yan
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [18] Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study
    Dalfino, Lidia
    Stufano, Monica
    Bavaro, Davide Fiore
    Diella, Lucia
    Belati, Alessandra
    Stolfa, Stefania
    Romanelli, Federica
    Ronga, Luigi
    Di Mussi, Rosa
    Murgolo, Francesco
    Loconsole, Daniela
    Chironna, Maria
    Mosca, Adriana
    Montagna, Maria Teresa
    Saracino, Annalisa
    Grasso, Salvatore
    ANTIBIOTICS-BASEL, 2023, 12 (06):
  • [19] Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study
    Oliva, Alessandra
    Bianchi, Alessandro
    Russo, Alessandro
    Ceccarelli, Giancarlo
    Cancelli, Francesca
    Aloj, Fulvio
    Alunni Fegatelli, Danilo
    Mastroianni, Claudio Maria
    Venditti, Mario
    ANTIBIOTICS-BASEL, 2021, 10 (03):
  • [20] Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study (vol 25,390,2025)
    Bu, Wei
    Wang, Chengyu
    Wu, Yuan
    Zhang, Peng
    Zhang, Nengfang
    Han, Ying
    Xu, Xiaona
    Li, Sha
    Cai, Yan
    BMC INFECTIOUS DISEASES, 2025, 25 (01)